Cefaclor XR Shortage: What Providers and Prescribers Need to Know in 2026

Patients are increasingly reporting difficulty filling prescriptions for Cefaclor XR (cefaclor extended-release tablets) at community pharmacies. As a prescriber, understanding the supply landscape — and having a clinical strategy ready — can mean the difference between a patient completing their antibiotic course and returning with a worsened infection.

Current Availability Status (2026)

As of 2026, Cefaclor XR is not on the FDA's official Drug Shortage Database and has not been listed by ASHP as a formal shortage. However, prescribers should be aware of the following realities:

The original brand (Ceclor CD) is discontinued. Only generic versions remain available, currently manufactured by a limited number of suppliers including Teva Pharmaceuticals USA.

Low prescription volume means most retail pharmacies do not routinely stock Cefaclor XR. It is often available only by special order from the pharmacy's wholesaler, with a 1-3 business day lead time.

The extended-release formulation's strict food requirement (must be taken with food; without food, Cmax drops by approximately 67%) means it cannot simply be replaced by doubling the immediate-release capsule dose.

Rural and smaller community pharmacies are less likely to carry it than urban or hospital-affiliated pharmacies.

Clinical Pharmacology Reminder: XR vs. IR Formulations

The Cefaclor XR formulation differs pharmacokinetically from immediate-release (IR) capsules in important ways prescribers should keep in mind:

500 mg Cefaclor XR twice daily = 250 mg IR capsule every 8 hours (NOT 500 mg IR capsule twice daily — these are not bioequivalent)

Food significantly increases XR absorption; Cmax is approximately 12% lower and AUC is 10% lower even when taken with food compared to IR capsules — but without food, absorption drops dramatically

The plasma half-life averages approximately 1 hour regardless of formulation; no drug accumulation occurs with twice-daily dosing

Safety and efficacy of the ER formulation has not been established in patients under 16 years of age

FDA-Approved Indications for Cefaclor XR

Cefaclor XR is approved specifically for mild-to-moderate infections:

Acute bacterial exacerbations of chronic bronchitis (ABECB) due to H. influenzae (excluding beta-lactamase-negative, ampicillin-resistant isolates), M. catarrhalis, or S. pneumoniae

Secondary bacterial infections of acute bronchitis due to H. influenzae, M. catarrhalis, or S. pneumoniae

Pharyngitis and tonsillitis due to S. pyogenes

Uncomplicated skin and skin-structure infections due to S. aureus or S. pyogenes

Note: The safety and effectiveness of Cefaclor XR for treating some of the indications approved for other cefaclor formulations have NOT been established. Confirm the specific indication before prescribing.

Clinical Alternatives to Consider

When Cefaclor XR is unavailable, the following are commonly considered alternatives depending on the clinical indication:

Cefuroxime axetil (Ceftin): Most clinically similar second-gen cephalosporin; 250-500 mg BID with food; widely available as generic; covers same respiratory pathogens

Cefdinir: Third-gen oral cephalosporin; 300 mg BID or 600 mg QD; can be taken without food; broader gram-negative coverage; widely stocked

Amoxicillin-clavulanate (Augmentin): 875/125 mg BID; appropriate for non-penicillin-allergic patients; good coverage for ABECB and sinusitis

Cefprozil: Second-gen cephalosporin; 250-500 mg BID; similar spectrum; can be taken with or without food; availability varies

Renal Dosing Considerations

For patients with renal impairment, cefaclor dosing should be adjusted:

CrCl 10-30 mL/min: Reduce dose by 50%

CrCl <10 mL/min: Reduce dose by 75% (high doses may cause CNS toxicity)

Geriatric patients (≥65 years) with normal serum creatinine: No dose adjustment required, but monitor for renal function changes

How to Help Your Patients Access Cefaclor XR

Consider recommending medfinder for providers to your patients. medfinder is a paid service that calls pharmacies near the patient to check which ones have the medication in stock, then texts the results. This can save significant time and reduce treatment delays when a drug has inconsistent pharmacy availability.

Additionally, consider noting on the prescription or in your patient instructions: "If unavailable at your pharmacy, ask for a special order or contact our office for an alternative." This simple note can reduce patient confusion and unnecessary emergency department visits.